Evidence map›Paper›PMID 37111528›Full record

ArticlePharmaceutics2023

Impact of Tablet Size and Shape on the Swallowability in Older Adults.

Henriette Hummler, Cordula Stillhart, Lisa Meilicke, Michael Grimm, Elischa Krause, Marwan Mannaa, Maik Gollasch, Werner Weitschies, Susanne Page

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Henriette HummlerPharma Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstr. 124, CH-4070 Basel, Switzerland.ORCID 0000-0002-7956-150X
Cordula StillhartPharma Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstr. 124, CH-4070 Basel, Switzerland.ORCID 0000-0002-5203-9842
Lisa MeilickeCenter of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.
Michael GrimmCenter of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.ORCID 0000-0002-1310-7435
Elischa KrauseDepartment of Psychiatry and Psychotherapy, University Medicine Greifswald, Ellernholzstr. 1/2, 17489 Greifswald, Germany.ORCID 0000-0002-7222-2249
Marwan MannaaDepartment of Internal Medicine and Geriatrics, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17489 Greifswald, Germany.
Maik GollaschDepartment of Internal Medicine and Geriatrics, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17489 Greifswald, Germany.
Werner WeitschiesCenter of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487 Greifswald, Germany.ORCID 0000-0003-3492-7747
Susanne PagePharma Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstr. 124, CH-4070 Basel, Switzerland.ORCID 0000-0003-2639-037X
Roche (Switzerland) · CHUniversität Greifswald · DEUniversitätsmedizin Greifswald · DE

Funding

European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 956146
6 · The paper itself

Abstract

Older adults represent the major target population for oral medications, due to the high prevalence of multimorbidity. To allow for successful pharmacological treatments, patients need to adhere to their medication and, thus, patient-centric drug products with a high level of acceptability by the end users are needed. However, knowledge on the appropriate size and shape of solid oral dosage forms, as the most commonly used dosage forms in older adults, is still scarce. A randomized intervention study was performed including 52 older adults (65 to 94 years) and 52 young adults (19 to 36 years). Each participant swallowed four coated placebo tablets differing in weight (250 to 1000 mg) and shape (oval, round, oblong) in a blinded manner on three study days. The choice of tablet dimensions allowed for a systematic comparison between different tablet sizes of the same shape, as well as between different tablet shapes. Swallowability was assessed using a questionnaire-based method. All tested tablets were swallowed by ≥80% of adults, independent of age. However, only the 250 mg oval tablet was classified as

Indexed as

geriatric patientsmedicine acceptabilityolder adultspreferencesolid oral dosage formsswallowability

Identifiers

PMID37111528
PMCPMC10145850
OpenAlexW4360865307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.